Open-label dose-escalation study of oral 1-octanol in patients with essential tremor

被引：38

作者：

Shill, HA

Bushara, KO

Mari, Z

Reich, M

Hallett, M

机构：

[1] NINDS, Human Motor Control Sect, Med Neurol Branch, NIH, Bethesda, MD 20892 USA

[2] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA

来源：

NEUROLOGY | 2004年 / 62卷 / 12期

关键词：

D O I：

10.1212/WNL.62.12.2320

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Twenty-one single oral doses of 1-octanol were given to patients with essential tremor ( ET) in an open-label dose-escalation study. The drug was well tolerated up to 64 mg/kg. The main side effect was an unusual taste. No overt intoxication was seen. There was evidence for efficacy, with a significant reduction in tremor amplitude as measured by accelerometry and handwriting that was maximal at 2 hours. Higher doses may produce more sustained benefit.

引用

页码：2320 / 2322

页数：3

共 50 条

[1] Dose-escalation study of oral 1-octanol in patients with essential tremor
Shill, HA
Reich, M
Bushara, KO
Grimes, G
Hallett, M
MOVEMENT DISORDERS, 2002, 17 : S346 - S346
[2] An Open-Label, Single-Dose, Crossover Study of the Pharmacokinetics and Metabolism of Two Oral Formulations of 1-Octanol in Patients with Essential Tremor
Fatta B. Nahab
Loretta Wittevrongel
Dominic Ippolito
Camilo Toro
George J Grimes
Judith Starling
Gopal Potti
Dietrich Haubenberger
Daniel Bowen
Peter Buchwald
Chuanhui Dong
Daniel Kalowitz
Mark Hallett
Neurotherapeutics, 2011, 8 : 753 - 762
[3] An Open-Label, Single-Dose, Crossover Study of the Pharmacokinetics and Metabolism of Two Oral Formulations of 1-Octanol in Patients with Essential Tremor
Nahab, Fatta B.
Wittevrongel, Loretta
Ippolito, Dominic
Toro, Camilo
Grimes, George J.
Starling, Judith
Potti, Gopal
Haubenberger, Dietrich
Bowen, Daniel
Buchwald, Peter
Dong, Chuanhui
Kalowitz, Daniel
Hallett, Mark
NEUROTHERAPEUTICS, 2011, 8 (04) : 753 - 762
[4] Dose-escalation study of octanoic acid in patients with essential tremor
Voller, Bernhard
Lines, Emily
McCrossin, Gayle
Tinaz, Sule
Lungu, Codrin
Grimes, George
Starling, Judith
Potti, Gopal
Buchwald, Peter
Haubenberger, Dietrich
Hallett, Mark
JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (04): : 1451 - 1457
[5] AN OPEN-LABEL DOSE-ESCALATION TRIAL OF ORAL DEHYDROEPIANDROSTERONE TOLERANCE AND PHARMACOKINETICS IN PATIENTS WITH HIV DISEASE
DYNER, TS
LANG, W
GEAGA, J
GOLUB, A
STITES, D
WINGER, E
GALMARINI, M
MASTERSON, J
JACOBSON, MA
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (05): : 459 - 465
[6] Long duration accelometry to assess efficacy of oral 1-octanol in patients with essential tremor
Nahab, F. B.
Babies, S.
Ippolito, D.
Hallett, M.
MOVEMENT DISORDERS, 2007, 22 : S294 - S295
[7] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Kropff, Martin
Kienast, Joachim
Bisping, Guido
Berdel, Wolfgang E.
Gaschler-Markefski, Birgit
Stopfer, Peter
Stefanic, Martin
Munzert, Gerd
ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
[8] Pilot trial of 1-octanol in essential tremor
Bushara, KO
Goldstein, SR
Grimes, GJ
Burstein, AH
Hallett, M
NEUROLOGY, 2004, 62 (01) : 122 - 124
[9] Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
Altman, Robert D.
Lang, Anthony E.
Postuma, Ronald B.
MOVEMENT DISORDERS, 2011, 26 (13) : 2427 - 2431
[10] An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
Savona, Michael R.
Odenike, Olatoyosi
Amrein, Philip C.
Steensma, David P.
DeZern, Amy E.
Michaelis, Laura C.
Faderl, Stefan
Harb, Wael
Kantarjian, Hagop
Lowder, James
Oganesian, Aram
Azab, Mohammad
Garcia-Manero, Guillermo
LANCET HAEMATOLOGY, 2019, 6 (04): : E194 - E203

← 1 2 3 4 5 →